Pharma deals risk healthcare access

An analysis suggests secretive pharma deals could undermine 'most-favored nation' pricing mechanisms, potentially raising drug costs for vulnerable populations. This friction threatens equitable acces

An analysis suggests secretive pharma deals could undermine 'most-favored nation' pricing mechanisms, potentially raising drug costs for vulnerable populations. This friction threatens equitable access to medicines—a basic need—by weakening price safeguards that typically keep medications affordable across borders.

The source is unreachable, so no verification exists here. This remains a theoretical risk without concrete evidence of deals or pricing impacts.

Source: STAT